Navigation Links
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
Date:8/6/2009

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's current plans to introduce a series of diagnostic tests, to add enhancements to the OncoCarta panel and to commercialize the AttoSense HPV test, the development of a Down syndrome test, including the conduct of clinical trials and the publication of the results of those trials, and the Company's ability to expand its genetic analysis platforms, as well as the statements under "2009 Guidance," are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's ability to develop and commercialize new technologies and products, particularly new technologies such as genetic analysis platforms, noninvasive prenatal diagnostics and laboratory developed tests, reliance upon the collaborative efforts of other parties, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, the independent investigation and other risks detailed from time to time in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this pres
'/>"/>

SOURCE SEQUENOM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. SEQUENOM Announces Launch of MassARRAY Compact 96 System
2. SEQUENOM to Hold First Quarter 2009 Financial Results Conference Call on April 30
3. Webcast Alert: Sequenom: Defining the Future of Noninvasive Prenatal Diagnostics
4. Sequenom to Webcast Analyst and Investor Briefing Presentation on June 3
5. Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24
6. OncoGenex Reports Second Quarter 2009 Financial Results
7. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
8. PDI Reports 2009 Second Quarter Financial Results
9. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
11. NxStage Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... This is a professional and in-depth ... The report provides basic biocides information, including its ... well as industry overview. This research covers the ... well as Global industry analysis covering macroeconomic environment ... Chinese biocides industry covers information on ...
(Date:10/31/2014)... ENVIRON , an international ... that Dr. Harvey Clewell III has rejoined the ... closely with senior professionals in ENVIRON’s Health Sciences ... at The Hamner Institutes for Health Sciences (The ... he is Director, Center for Human Health Assessment. ...
(Date:10/31/2014)... , Oct. 31, 2014  Atlanta-based Intellimedix could ... accompanying the onset of Ebola by suggesting a ... at Georgia Tech,s Center for Computational Systems Biology ... to find alternative uses for existing drugs through ... to aid the bout against Ebola. ...
(Date:10/30/2014)... 30, 2014  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that ... on Thursday, November 6, 2014. Following the announcement, ... conference call and webcast at 4:30pm ET to ... business update. The live webcast can ...
Breaking Biology Technology:Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 2Biocides Market for International & Chinese Regional Development Analysis Now Available at DeepResearchReports.com 3Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Atlanta-Based Intellimedix May Help Solve Ebola With Computer Algorithms 2Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2
... , , , , ... CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a ... the Second and final closing of a private placement financing with ... $5 million. , , As previously reported, ...
... CINCINNATI, Sept. 18 LCA-Vision Inc. (Nasdaq: LCAV ... the Lasik Plus (R) brand, announces that Steven C. Straus ... the company,s board of directors effective September 25, 2009 to ... Management of daily operations will be the responsibility of Chief ...
... 18 Omeros Corporation today announced the launch of its ... stock. Omeros is a clinical-stage biopharmaceutical company committed to ... of the central nervous system. , , ... $10.00 to $12.00 per share. Omeros has applied to ...
Cached Biology Technology:Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 2Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million 3LCA-Vision Announces CEO Resignation 2Omeros Commences Initial Public Offering of Common Stock 2Omeros Commences Initial Public Offering of Common Stock 3
(Date:10/29/2014)... hair as a consequence of chemotherapy will benefit from ... cooling technology that prevents hair loss. , The research ... global scalp cooling manufacturing company, Paxman Coolers, of Fenay ... the University of Huddersfield. , The research will be ... background in the pharmacology of cancer treatment, which he ...
(Date:10/29/2014)... for the Society of Interventional Radiology,s (SIR) ... the one place where interventional radiologists, diagnostic ... professionals can come together to find the ... presented, discussed and tested. , "Connecting ... medicine, SIR 2015 will feature essential updates ...
(Date:10/29/2014)... industrial products are in the environment – and hundreds ... scientists have yet to determine whether they cause health ... that by estimating which substances people are exposed to ... ACS journal Environmental Science & Technology . , ... to human health of any given substance depend primarily ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2SIR 2015: Interventional radiology shapes tomorrow's medicine 2
... University, the team mapped the presence of foxes in ... their likely distribution as a blueprint for fox eradication, ... of Canberra professor in wildlife genetics and leader of ... northern and eastern Tasmania and the model developed by ...
... CA Researchers from the Carnegie Institution are rolling out ... AToMS, for the first time at the American Geophysical ... and its scientific observations are uncovering a previously invisible ... is helping researchers look at the world in a ...
... MA and SAN FRANCISCO, CADecember 4, 2012 The ALS ... today announced the formation of a research collaboration to ... the preclinical drug development process. "We are ... ALS therapeutic development," said Steve Perrin, PhD, CEO and ...
Cached Biology News:Fox invasion threatens wave of extinction, UC research finds 2Carnegie debuts revolutionary biosphere mapping capability at AGU 2Carnegie debuts revolutionary biosphere mapping capability at AGU 3ALS TDI and Gladstone Institutes collaborate to discover potential ALS treatments 2
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
... 3 x 3 nmol (individual) with ... 3 siRNAs specifically targeted to your target gene ... reagent guarantees you get more than 75% knockdown ... conditions (100 nM siRNA for transfection and confirmation ...
... siTrio siRNA --- a cocktail of 3 ... of interestis our most popular product. The ... 75% knockdown of your target gene when ... for transfection and confirmation of optimal transfection ...
... IDS 25-Hydroxy Vitamin D kit is ... determination of 25-hydroxyvitamin D (25-OH D) ... serum or plasma. Our patented DIRECT ... solvent precipitation and centrifugation and therefore ...
Biology Products: